FDA Cosmetic-Drug Monograph Process Should Be Referred To CIR - OTC Mtg.
This article was originally published in The Rose Sheet
Executive Summary
FDA should refer the review of cosmetic active ingredients to the Cosmetic Ingredient Review panel rather than spend extended time developing monographs, consultant David Steinberg (Steinberg & Associates) said at a public hearing on OTC drug regulation in Gaithersburg, Md. June 28-29.